Peripheral blood mononuclear cell therapy in PAD patients

Peripheral blood mononuclear cell therapy in PAD patients - PB-MNC therapy (PERTIENT) trial II

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000764

Enrollment

Registered

2007-07-10

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease due to collagen disease

Interventions

PB-MNC implantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PAD patients presenting with severe ischemia resistant to conventional therapies

Exclusion criteria

Exclusion criteria: Patients with malignant diseases, severe diabetic retinopathy, or severe renal failure.

Design outcomes

Primary

Measure	Time frame
Major amputation	—

Secondary

Measure	Time frame
Laser Doppler Image, Scintigraphy, MRI, Angiography, ABI, improvement of ischemic ulcer and pain, QOL estimation	—

Countries

Japan

Contacts

Public ContactTohru Minamino

Chiba University Hospital Department of Cardiovascular Medicine

t_minamino@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026